Article ID Journal Published Year Pages File Type
9320759 European Urology Supplements 2005 8 Pages PDF
Abstract
All three tamsulosin OCAS doses tested were effective in relieving urinary symptoms and improving disease-specific quality of life in LUTS/BPH patients. The 0.8 mg and, in particular, the 0.4 mg doses were better tolerated than the 1.2 mg dose. Therefore, these two doses were selected for further evaluation in a phase 3a placebo- and comparator (tamsulosin modified release capsules) controlled trial.
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , , ,